Literature DB >> 26970273

Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances.

Susan Pyne1, David R Adams2, Nigel J Pyne3.   

Abstract

Sphingosine kinases (isoforms SK1 and SK2) catalyse the formation of a bioactive lipid, sphingosine 1-phosphate (S1P). S1P is a well-established ligand of a family of five S1P-specific G protein coupled receptors but also has intracellular signalling roles. There is substantial evidence to support a role for sphingosine kinases and S1P in health and disease. This review summarises recent advances in the area in relation to receptor-mediated signalling by S1P and novel intracellular targets of this lipid. New evidence for a role of each sphingosine kinase isoform in cancer, the cardiovascular system, central nervous system, inflammation and diabetes is discussed. There is continued research to develop isoform selective SK inhibitors, summarised here. Analysis of the crystal structure of SK1 with the SK1-selective inhibitor, PF-543, is used to identify residues that could be exploited to improve selectivity in SK inhibitor development for future therapeutic application.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Intracellular signalling; S1P receptors; Sphingosine 1-phosphate; Sphingosine kinase; Sphingosine kinase inhibitors

Mesh:

Substances:

Year:  2016        PMID: 26970273     DOI: 10.1016/j.plipres.2016.03.001

Source DB:  PubMed          Journal:  Prog Lipid Res        ISSN: 0163-7827            Impact factor:   16.195


  64 in total

1.  Measurement of Lysophosphatidic Acid and Sphingosine-1-Phosphate by Liquid Chromatography-Coupled Electrospray Ionization Tandem Mass Spectrometry.

Authors:  Maria P Kraemer; Suchismita Halder; Susan S Smyth; Andrew J Morris
Journal:  Methods Mol Biol       Date:  2018

2.  A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.

Authors:  Carolyn D Britten; Elizabeth Garrett-Mayer; Steven H Chin; Keisuke Shirai; Besim Ogretmen; Tricia A Bentz; Alan Brisendine; Kate Anderton; Susan L Cusack; Lynn W Maines; Yan Zhuang; Charles D Smith; Melanie B Thomas
Journal:  Clin Cancer Res       Date:  2017-04-18       Impact factor: 12.531

3.  Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.

Authors:  Samy A F Morad; Traci S Davis; Matthew R MacDougall; Su-Fern Tan; David J Feith; Dhimant H Desai; Shantu G Amin; Mark Kester; Thomas P Loughran; Myles C Cabot
Journal:  Biochem Pharmacol       Date:  2017-02-09       Impact factor: 5.858

Review 4.  Orm/ORMDL proteins: Gate guardians and master regulators.

Authors:  Deanna Davis; Muthukumar Kannan; Binks Wattenberg
Journal:  Adv Biol Regul       Date:  2018-08-31

Review 5.  Targeting Sphingosine Kinases for the Treatment of Cancer.

Authors:  Clayton S Lewis; Christina Voelkel-Johnson; Charles D Smith
Journal:  Adv Cancer Res       Date:  2018-06-09       Impact factor: 6.242

6.  Ceramide synthase inhibition by fumonisins: a perfect storm of perturbed sphingolipid metabolism, signaling, and disease.

Authors:  Ronald T Riley; Alfred H Merrill
Journal:  J Lipid Res       Date:  2019-05-02       Impact factor: 5.922

Review 7.  Sphingosine-1-phosphate receptors and innate immunity.

Authors:  Arielle M Bryan; Maurizio Del Poeta
Journal:  Cell Microbiol       Date:  2018-03-23       Impact factor: 3.715

Review 8.  Sphingolipids in spinal cord injury.

Authors:  Zachary B Jones; Yi Ren
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2016-08-05

Review 9.  Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.

Authors:  C Evangelisti; C Evangelisti; F Buontempo; A Lonetti; E Orsini; F Chiarini; J T Barata; S Pyne; N J Pyne; A M Martelli
Journal:  Leukemia       Date:  2016-07-27       Impact factor: 11.528

Review 10.  Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.

Authors:  Victoria A Blaho
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.